Published in J Am Acad Dermatol on August 14, 2009
Endogenous retinoids in the pathogenesis of alopecia areata. J Invest Dermatol (2012) 1.28
Management of alopecia areata. BMJ (2010) 1.25
Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol (2011) 0.82
Bexarotene gel: a new topical therapy for alopecia areata. Int J Trichology (2010) 0.78
Treatment of alopecia universalis with oral alitretinoin: A case report. JAAD Case Rep (2017) 0.75
Current treatment strategies in pediatric alopecia areata. Indian J Dermatol (2012) 0.75
Alopecia Areata: An Update on Treatment Options for Children. Paediatr Drugs (2017) 0.75
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med (2011) 5.60
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol (2002) 2.26
Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood (2002) 2.20
The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy. Int J Cardiovasc Imaging (2009) 2.13
Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther (2002) 2.07
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer (2011) 2.02
History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol (2009) 1.96
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs (2007) 1.95
Design considerations and rationale of a multi-center trial to sustain weight loss: the Weight Loss Maintenance Trial. Clin Trials (2008) 1.89
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol (2005) 1.71
Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol (2007) 1.65
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer (2010) 1.64
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood (2009) 1.62
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood (2004) 1.60
Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood (2007) 1.59
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood (2004) 1.58
Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet (2007) 1.55
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol (2002) 1.54
p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol (2003) 1.54
Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol (2002) 1.54
Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol (2004) 1.53
Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst (2003) 1.42
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
Mycosis fungoides with tinea pseudoimbricata owing to Trichophyton rubrum infection. J Cutan Med Surg (2007) 1.39
Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res (2012) 1.39
Cutaneous manifestations of Hodgkin's disease. Int J Dermatol (2006) 1.36
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res (2004) 1.33
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol (2010) 1.29
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Skin cancer detection by spectroscopic oblique-incidence reflectometry: classification and physiological origins. Appl Opt (2004) 1.22
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat (2008) 1.22
Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis (2008) 1.22
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol (2010) 1.20
Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol (2009) 1.18
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood (2012) 1.15
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood (2007) 1.14
Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol (2008) 1.12
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol (2006) 1.12
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood (2002) 1.10
Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg (2012) 1.10
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res (2002) 1.10
Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol (2012) 1.09
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis (2006) 1.09
Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood (2005) 1.09
Skin lesions associated with Fusarium infection. J Am Acad Dermatol (2002) 1.09
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab (2015) 1.08
Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer (2008) 1.06
Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol (2012) 1.05
Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. J Natl Compr Canc Netw (2008) 1.04
In-vivo characterization of optical properties of pigmented skin lesions including melanoma using oblique incidence diffuse reflectance spectrometry. J Biomed Opt (2011) 1.04
Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol (2009) 1.02
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife (2013) 1.02
Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol (2010) 1.01
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem (2012) 1.01
Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics (2006) 1.00
Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load. J Clin Microbiol (2004) 0.99
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res (2007) 0.99
High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. Melanoma Res (2006) 0.98
Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.98
Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle (2014) 0.97
Adult Langerhans cell histiocytosis limited to the skin. Dermatology (2003) 0.97
Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol (2006) 0.97
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest (2016) 0.96
Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol (2003) 0.96
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma (2012) 0.96
Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol (2011) 0.96
Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol (2010) 0.95
A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol (2012) 0.95
Increased malignancy risk in the cutaneous T-cell lymphoma patient population. Clin Lymphoma Myeloma (2008) 0.95
Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol (2007) 0.95
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol (2010) 0.94
Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) (2007) 0.94
Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol (2002) 0.93
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant (2012) 0.92
Human leukocyte antigen class II alleles are associated with risk of alopecia areata. J Invest Dermatol (2007) 0.92
Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk (2011) 0.92
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol (2013) 0.92
In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst (2005) 0.92
Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol (2008) 0.92
Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. J Invest Dermatol (2008) 0.91
Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther (2003) 0.91
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther (2007) 0.91
Triterpenoid electrophiles (avicins) suppress heat shock protein-70 and x-linked inhibitor of apoptosis proteins in malignant cells by activation of ubiquitin machinery: implications for proapoptotic activity. Clin Cancer Res (2005) 0.91
Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma (2006) 0.90